Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017


The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.
Insights on pipeline segments
As per the findings of the research, most of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route.
Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development
MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of their drug candidates in chronic obstructive pulmonary disease. The technology is used for the in vitro generation of highly specific and fully human antibodies.
Request sample market report here : http://bit.ly/2Dy1Ek3
Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline
The research found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to AstraZeneca plc for benralizumab in Asia.
Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and others.
Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis
  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company
Access market report summary here : https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

Comments

Post a Comment

Popular posts from this blog

Clinical Decision Support System (CDSS) Market Segment Forecasts - 2022

Image
Market Synopsis of Clinical Decision Support System : The global CDSS Market was valued at $410.5 million in 2015, and it is expected to grow at a CAGR of 21.5% during 2016-2022. Among the various products, the integrated Clinical Decision Support System segment is expected to witness the fastest growth, CAGR of 22.4%, during the forecast period. The global CDSS market is growing at a significant rate, due to growing demand for advanced healthcare information systems, and growing investments by HIT players. In addition, the growing need for remote patient monitoring services and increasing support from government organizations is also driving the growth of the global CDSS market. Read market summary report here : http://bit.ly/2tF1nMJ Regional Analysis of Clinical Decision Support System Market Geographically, North America dominated the global market of CDSS in 2015; whereas the Asia-Pacific market is expected to witness the fastest growth at a CAGR of 23.2%, during the fo...
Read more